Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KDM6B | O15054 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2846899 | 0.95 | SMN1; SMN2 (0.50) | KDM4ERAB9ASMN1; SMN2NPC1EPHX2 | |
| SCHEMBL2840635 | 0.93 | TRPV1 (0.53) | KDM4ERAB9ASMN1; SMN2NPC1HPGD | |
| SCHEMBL334624 | 0.93 | TRPV1 (0.53) | KDM4ERAB9ASMN1; SMN2NPC1HPGD | |
| SCHEMBL334426 | 0.89 | SMN1; SMN2 (0.63) | KDM4ERAB9ASMN1; SMN2NPC1HDAC2 | |
| SCHEMBL3049837 | 0.84 | KDM4E (0.49) | KDM4EL3MBTL1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL164622 | 0.82 | L3MBTL1 (0.72) | KDM4EL3MBTL1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL2357555 | 0.82 | RAB9A (0.79) | KDM4ERAB9ASMN1; SMN2NPC1EPHX2 | |
| SCHEMBL19133494 | 0.81 | ALDH1A1 (0.65) | SMN1; SMN2GAACYP2D6CYP2C19 | |
| SCHEMBL18381418 | 0.80 | LMNA (0.68) | KDM4EL3MBTL1SMN1; SMN2HPGDGAA | |
| SCHEMBL23291153 | 0.80 | EPHX2 (0.53) | RAB9ASMN1; SMN2NPC1EPHX2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964654-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | Glaxosmithkline LLC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002273-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-01-07 | — | — | US | disclosed |
| WO-2014138562-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-09-12 | — | — | WO | disclosed |
| EP-2251324-A1 | HETEROARYL-ALKYLCARBAMATE COMPOUNDS AND THEIR USE AS INHIBITORS OF THE FAAH ENZYME | Sanofi-Aventis (FR) | 2010-11-17 | — | — | EP | disclosed |
| EP-1720829-B1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI AVENTIS (FR) | 2009-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002273-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | SIRT2, SIRT1, SIRT6 | KDM4E 533/4885L3MBTL1 3141/4885RAB9A 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.